An prospective, open-label, random and control clinical trail of Apatinib combined with TACE contrast to the simple TACE in the treatment of recurrent hepatocellular carcinoma (HCC)

Trial Profile

An prospective, open-label, random and control clinical trail of Apatinib combined with TACE contrast to the simple TACE in the treatment of recurrent hepatocellular carcinoma (HCC)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Apatinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top